CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14

Akalin, 2020, Covid-19 and kidney transplantation, N Engl J Med, 10.1056/NEJMc2011117 Aran, 2019, Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage, Nat Immunol, 20, 163, 10.1038/s41590-018-0276-y Channappanavar, 2017, Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology, Semin Immunopathol, 39, 529, 10.1007/s00281-017-0629-x Chen, 2020, Functional roles of CCL5/RANTES in liver disease, Liver Res, 4, 28, 10.1016/j.livres.2020.01.002 Chua, 2020, COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis, Nat Biotechnol, 8, 970, 10.1038/s41587-020-0602-4 ClinicalTrials.gov-Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to ModerateCOVID-19. https://clinicaltrials.gov/ct2/show/NCT04343651.ClinicalTrials.gov, Study to Evaluate the Efficacy and Safety of Leronlimab for Patients with Severe or Critical Coronavirus Disease 2019 (COVID-19). https://clinicaltrials.gov/ct2/show/NCT04347239. Dhody, 2018, PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infection, HIV Clin Trials, 19, 85, 10.1080/15284336.2018.1452842 Grillet, 2020, Acute pulmonary embolism associated with COVID-19 pneumonia detected by pulmonary CT angiography, Radiology, 10.1148/radiol.2020201544 Halama, 2016, Tumoral immune cell exploitation in colorectal cancer metastases can be targeted effectively by anti-CCR5 therapy in cancer patients, Cancer Cell, 29, 587, 10.1016/j.ccell.2016.03.005 Huang, 2020, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, 395, 497, 10.1016/S0140-6736(20)30183-5 Jacobson, 2008, Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults, J Infect Dis, 198, 1345, 10.1086/592169 Jacobson, 2010, Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody, J Infect Dis, 201, 1481, 10.1086/652190 Jacobson, 2010, Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults, Antimicrob Agents Chemother, 54, 4137, 10.1128/AAC.00086-10 Law, 2005, Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells, Blood, 106, 2366, 10.1182/blood-2004-10-4166 Lescure, 2020, Clinical and virological data of the first cases of COVID-19 in Europe: a case series, Lancet Infect Dis, 10.1016/S1473-3099(20)30200-0 Li, 2020, Clinical and pathological investigation of patients with severe COVID-19, JCI Insight, 5, 10.1172/jci.insight.138070 Machlus, 2016, CCL5 derived from platelets increases megakaryocyte proplatelet formation, Blood, 127, 921, 10.1182/blood-2015-05-644583 Mehta, 2020, COVID-19: consider cytokine storm syndromes and immunosuppression, Lancet, 395, 1033, 10.1016/S0140-6736(20)30628-0 Mottet, 2020 Nicholls, 2003, Lung pathology of fatal severe acute respiratory syndrome, Lancet, 361, 1773, 10.1016/S0140-6736(03)13413-7 Olson, 1999, Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5, J Virol, 73, 4145, 10.1128/JVI.73.5.4145-4155.1999 Qin, 2020, Dysregulation of immune response in patients with COVID-19 in Wuhan, China, Clin Infect Dis, 71, 762, 10.1093/cid/ciaa248 Richardson, 2020, Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area, JAMA, 26, 2052, 10.1001/jama.2020.6775 Schroth, 1999, Rhinovirus replication causes RANTES production in primary bronchial epithelial cells, Am J Respir Cell Mol Biol, 20, 1220, 10.1165/ajrcmb.20.6.3261 Vincent, 2004, IL-6 regulates CD44 cell surface expression on human myeloma cells, Leukemia, 18, 967, 10.1038/sj.leu.2403333 World Health Organization. Coronavirus Disease (COVID-2019) Situation Reports. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. [Accessed 23 April 2020]. Yen, 2006, Modeling the early events of severe acute respiratory syndrome coronavirus infection in vitro, J Virol, 80, 2684, 10.1128/JVI.80.6.2684-2693.2006 Yu, 2016, RANTES mediates kidney ischemia reperfusion injury through a possible role of HIF-1α and LncRNA PRINS, Sci Rep, 6, 18424, 10.1038/srep18424 Zhao, 2020, Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild disease, JCI Insight, 5, 10.1172/jci.insight.139834